Paclitaxel, uracil plus tegafur (UFT) and leucovorin (LV) in patients with pre-treated metastatic breast cancer: Preclinical rationale and phase I study results

被引：0
|
作者：
Passardi, A. [1 ]
Massa, I. [1 ]
Milandri, C. [1 ]
Cecconetto, L. [1 ]
Calpona, S. [1 ]
Ibrahim, T. [1 ]
Ridolfi, L. [1 ]
Zoli, W. [1 ]
Frassineti, L. [1 ]
Maltoni, R. [1 ]
机构：
[1] Ist Oncol Romagnolo, Forll, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI11 / XI12
页数：2
相关论文
共 50 条
  • [1] A phase I study of oral uracil/tegafur (UFT) plus leucovorin (LV) combined with oxaliplatin in patients with metastatic colorectal cancer (CRC).
    Douillard, JY
    Dissoubray, C
    Seitz, JF
    CLINICAL CANCER RESEARCH, 2000, 6 : 4574S - 4574S
  • [2] Oral uracil/tegafur (UFT) plus leucovorin (LV) in patients with metastatic colorectal cancer (CRC)
    Goker, E
    Aykan, NF
    Serdengecti, S
    Gunel, N
    Alakavuklar, M
    Icli, F
    Yucel, I
    Uskent, N
    Arpaci, F
    Firat, D
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S78 - S78
  • [3] Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients
    Koji Okabayashi
    Hirotoshi Hasegawa
    Yoshiyuki Ishii
    Takashi Endo
    Hiroki Ochiai
    Tetsuro Kubota
    Yuko Kitagawa
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 501 - 507
  • [4] Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients
    Okabayashi, Koji
    Hasegawa, Hirotoshi
    Ishii, Yoshiyuki
    Endo, Takashi
    Ochiai, Hiroki
    Kubota, Tetsuro
    Kitagawa, Yuko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (03) : 501 - 507
  • [5] A phase I/II study of tegafur-uracil (UFT) plus oral leucovorin (LV) and biweekly CPT-11 therapy for patients (pts) with metastatic colorectal cancer (CRC).
    Uetake, H
    Tetsuro, H
    Enomoto, M
    Sugihara, K
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 303S - 303S
  • [6] Phase II randomized study of oral uracil/tegafur (UFT) plus leucovorin (LV) or parenteral 5-Fluorouracil (5-FU) plus leucovorin in patients with metastatic colorectal cancer (MCRC)
    Sizer, B.
    Makris, A.
    Barone, C.
    Bordonaro, R.
    Hausmaninger, H.
    Steger, G.
    Aloe, A.
    Peeters, O.
    Donato, B.
    ANNALS OF ONCOLOGY, 2004, 15 : 93 - 93
  • [7] Phase I study of paclitaxel and uracil plus Tegafur combination in patients with pretreated metastatic breast cancer: Drug sequencing based on preclinical modelling studies
    Passardi, A.
    Maltoni, R.
    Milandri, C.
    Cecconetto, L.
    Massa, I.
    Zoli, W.
    Tesei, A.
    Fabbri, F.
    Nanni, O.
    Amadori, D.
    ONCOLOGY, 2007, 72 (1-2) : 118 - 124
  • [8] Phase I/II study of weekly paclitaxel (P), UFT and leucovorin in patients with metastatic breast cancer
    Chang, AY
    Beith, J
    Yeo, W
    Boyer, M
    Wong, J
    Lim, SE
    Chan, AT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 59S - 59S
  • [9] A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer
    Mackay, HJ
    Hill, M
    Twelves, C
    Glasspool, R
    Price, T
    Campbell, S
    Massey, A
    Macham, MA
    Uzzel, M
    Bailey, SM
    Martin, C
    Cunningham, D
    ANNALS OF ONCOLOGY, 2003, 14 (08) : 1264 - 1269
  • [10] Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur uracil
    Osaki, Akihiko
    Mitsuyama, Shoshu
    Kurebayashi, Jun-Ichi
    Sonoo, Hiroshi
    Nishimura, Reiki
    Koga, Toshihiro
    Murakami, Shigeru
    Ohno, Shinji
    ONCOLOGY LETTERS, 2010, 1 (01) : 45 - 49
12345